Verily, Sanofi and other industry players team up with NIH to advance Parkinson ’ s therapies

The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition.
Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the groups plan to commit $12 million to effort, which the NIH is slated to match.
Get the full story at our sister site, Drug Delivery Business News.
The post Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies appeared first on MassDevice.

Source: Mass Device - January 30, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Diagnostics Neurological Pharmaceuticals Wall Street Beat Celgene GlaxoSmithKline plc National Institutes of Health (NIH) Pfizer Sanofi-Aventis Verily Source Type: news